Current Report Filing (8-k)
August 12 2020 - 1:20PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
__________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of
Report (date of earliest event reported): August 12,
2020
SANUWAVE HEALTH, INC.
(Exact
Name of Registrant as Specified in its Charter)
Nevada
|
000-52985
|
20-1176000
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification Number)
|
3360 Martin Farm Road, Suite 100
Suwanee, Georgia 30024
(Address
of Principal Executive Offices, Including Zip Code)
(770) 419-7525
(Registrant’s
Telephone Number, Including Area Code)
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
Common Stock, par value $0.001
|
SNWV
|
OTCQB
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this
chapter).
Emerging
growth company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
Item 7.01 Regulation FD Disclosure.
The
investor presentation to be provided by SANUWAVE Health, Inc.
during its investor teleconference on August 12, 2020 is furnished
hereto as Exhibit 99.1.
The information in this Item 7.01 of this Current Report on Form
8-K and Exhibit 99.1 attached hereto shall not be deemed to be
“filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, and shall not be deemed
incorporated by reference in any filing under the Securities Act of
1933, as amended, except as shall be expressly set forth by
specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit Number
|
Description
|
|
Investor Presentation dated August 12, 2020.
|
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date:
August 12, 2020
|
SANUWAVE HEALTH, INC.
|
|
By: /s/
Lisa E. Sundstrom
|
|
Lisa E.
Sundstrom
Chief
Financial Officer
|
|
|
SANUWAVE Health (QB) (USOTC:SNWV)
Historical Stock Chart
From Aug 2024 to Sep 2024
SANUWAVE Health (QB) (USOTC:SNWV)
Historical Stock Chart
From Sep 2023 to Sep 2024